口服伊曲康唑治疗皮肤浅部真菌病200例临床观察

Oral Itraconazole for Superficial Dermatomycosis:A Clinical Series of 200 Patients

目的:观察口服伊曲康唑治疗皮肤浅部真菌感染的疗效及安全性。方法:选择200例临床及真菌学确诊皮肤浅部真菌感染患者,分为手足癣和体股癣治疗组。手足癣组口服伊曲康唑200 mg,bid;体股癣组口服200 mg,qd,均连服7天,停药3周后评价疗效。结果:手足癣治疗组痊愈率、总有效率和真菌清除率分别为59.38%、82.81%和92%;体股癣治疗组分别为68.06%、87.50%和94%。总不良反应发生率为5.5%。结论:口服伊曲康唑治疗皮肤浅部真菌病临床疗效好,可靠安全。

Objective： To evaluate the effectiveness and safety of itraconazole for superficial dermatomycosis. Methods： A series of 200 patients with dermatomycosis confirmed clinically and myeologically were divided into tinea manus and pedis group and tinea corporis group. 200 mg Itraconazole was given to two groups twice and once per day respectively. The treatment lasted for 7 days. The effectiveness was evaluated 3 weeks after withdrawal. Results： The rates of healing, total effective and fungal clearance in tinea manus and pedis group were 59.38%, 82.81% and 92%; and the rates in tinea corporis group were 68.06%, 87.50%and 94%. The total incidence of adverse effect was 5.5%. Conclusion： Oral itraconazole was effective and safe for superficial dermatomycosis.